Correct. Rules also change when it’s obvious they need to. For example when a platform technology using an indication agnostic approach is trialed and granted approval in a single indication but has demontrated benefit in others already as expected because of the very nature of the cell maturation and activation process being utilized in the treatment to identify potentially all antigen targets for any given disease state whether in vivo or ex vivo. Will patient awareness and demand exceed regulator ability to control “the process”?; ). Best wishes.
Market Data 
Markets 
AI
